A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 01 Sep 2017 Results (n=16) published in the Clinical Pharmacology in Drug Development : 2017 Annual Meeting of the American College of Clinical Pharmacology.
- 10 Jun 2017 Biomarkers information updated
- 26 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Jul 2018.